Navigation Links
Celladon Corporation Receives Patent from United States Patent and Trademark Office
Date:7/19/2012

SAN DIEGO, July 19, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,221,738 with claims that cover the administration of MYDICAR, Celladon's first in class drug under clinical evaluation for advanced heart failure. The patent, titled "Methods of enhanced uptake of viral vectors in the myocardium" carries a patent term to at least March, 2030. A similar application has been filed with the EU Patent Office (EPO).

"This is yet another important addition to our evolving patent portfolio for MYDICAR. The allowance further strengthens MYDICAR's market exclusivity protection in the United States" said Krisztina Zsebo Ph.D., President and CEO of Celladon Corp. "This is the second important patent granted to MYDICAR this year and we will continue the pursuit of additional patent grants relevant to our products on a global basis."

About MYDICAR

MYDICAR is a genetically targeted enzyme replacement therapy intended to restore levels of SERCA2a, a regulator of calcium cycling in the heart and cardiac contractility. SERCA2a levels decline in all forms of late-stage heart failure resulting in deficient heart function. With MYDICAR, the SERCA2a gene is delivered using recombinant adeno-associated virus (AAV) as the vector. AAV is a naturally occurring virus not associated with any disease in humans. MYDICAR is delivered in a single dose directly to the heart during a routine outpatient cardiac catheterization procedure, similar to an angiogram. MYDICAR is synergistic and additive across current heart failure treatments such as ACE inhibitors, beta-blockers, sprinolactone/diuretics, and biventricular pacing devices. No treatment substitution decision is required by the treating physician.

About Heart Failure

Chronic heart failure is a leading cause of hospitalization and is expected to result in direct and indirect costs of $39.2 billion to the U.S. healthcare system in 2010. Nearly 6 million people in the U.S. have heart failure, and at least 670,000 new cases will be diagnosed this year. Heart failure leads to about 280,000 deaths annually. The most common symptoms of heart failure are shortness of breath, feeling tired and swelling in the ankles, feet, legs and sometimes the abdomen. There is no cure.


'/>"/>
SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Celladon Corporation Receives Notice of Allowance from European Patent Office
2. Gentris Corporation Launches New Pharmacogenomics Services
3. BioElectronics Corporation Announces Initiative for UK and German Markets
4. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
5. Luminex Corporation Announces Agreement to Acquire GenturaDx
6. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
7. Gentris Corporation Partners with the Shanghai Institutes of Preventative Medicine
8. BioElectronics Corporation Announces Indian Distributors Ecommerce Website
9. FMC Corporation Acquires Phytone, Ltd., a Leading European Natural Colors Business
10. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
11. Centene Corporation Selected for Ohio Medicaid Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... -- Ampronix is excited to announce that we now stock the ( most advanced surgical and ... UHD camera was released to the consumer market in March 2016. Photo - ... ... ... The finely crafted GP-UH532 camera is the newest iteration of Panasonic,s 1080p HD ...
(Date:5/6/2016)... According to a new ... (Sso-PCR, Ssp-PCR, NGS, Sanger,s Sequencing), Products & Services ... (Hospitals, Academia, Diagnostic Center) - Forecast to 2021", ... to reach USD 753.9 Million by 2021 from ... of 7.1% from 2016 to 2021. ...
(Date:5/6/2016)... May 6, 2016  Hill-Rom Holdings, Inc. (NYSE: ... declared a fiscal year 2016 third quarter dividend of $0.17 per ... over the amount paid a year ago. The dividend ... of the close of business on June 10, 2016. ... Hill-Rom is a leading global medical technology company with ...
Breaking Medicine Technology:
(Date:5/6/2016)... Miami, Florida (PRWEB) , ... May 06, 2016 , ... ... scratching their heads as they try to get rid of the bugs and keep ... left trying to figure out how to protect their kids and their homes from ...
(Date:5/6/2016)... Irving, TX (PRWEB) , ... May 06, 2016 ... ... from offices in Irving, TX has announced the latest beneficiary of their ongoing ... a local family battling childhood leukemia. Young Mason McGaughey faces many more months ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... of a master charity program created to support and assist the people of ... days, working closely with nonprofit organizations and community leaders. Their desire is to ...
(Date:5/6/2016)... and LONDON, UK (PRWEB) , ... May 06, 2016 , ... ... for his success in changing the way the pharmaceutical industry conducts clinical trials. This ... the world’s most influential people in pharma, and he was honored as a Tech ...
(Date:5/6/2016)... ... , ... The joy associated with Mother’s Day is mixed with worry and fear for new ... across the country. For the first time ever, the March of Dimes and ... their Mother’s Day beside a crib surrounded by lifesaving equipment or peering through a glass ...
Breaking Medicine News(10 mins):